Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent

5 THINGS PATIENTS SHOULD KNOW BEFORE CONSIDERING TREATMENT


News provided by

Allergan

Mar 02, 2015, 09:07 ET

Share this article

Share toX

Share this article

Share toX

IRVINE, Calif., March 2, 2015 /PRNewswire/ -- According to statistics released by the American Society of Plastic Surgeons (ASPS), the use of Hyaluronic Acid (HA) dermal fillers, such as the JUVEDERM® family of fillers continues to increase.1 The ASPS data shows that between 2013 to 2014, HA filler treatments increased by 8 percent.1 This growth is supported by marketplace data which shows U.S. unit sales of HA dermal fillers were up by 17 percent in 2014.2 

"These findings are consistent with what I see every day in my practice. Over the past few years, I have noticed a sharp increase in patients asking about non-surgical treatments such as dermal fillers. Patients are looking for aesthetic treatments that are relatively quick," said Dr. David Bank, Assistant Clinical Professor of Dermatology at Columbia Presbyterian Medical Center in New York. "HA fillers, like the JUVEDERM® family of fillers, are made from a modified form of hyaluronic acid, which is a natural substance that occurs within the body.  JUVEDERM® XC and JUVEDERM VOLUMA® XC each offer patients natural-looking and long-lasting results."

Dermal fillers, also known as "soft-tissue fillers," do just what their name suggest: an HA filler like JUVEDERM® XC can be used to fill in the area under the skin to help temporarily diminish facial lines. While a product like JUVEDERM VOLUMA® XC can help restore volume lost due to aging to the cheek area. "Every day patients ask me for more information on dermal fillers," said Dr. Bank. "Here are the top five things I believe everyone considering treatment with a dermal filler should know."

Dr. David Bank's 5 Things You Should Know When Considering Fillers:

1.   What are fillers used for?

Over time your skin loses elasticity and moisture. A number of factors, including genetics, the environment and stress can cause deeper facial lines to form. My patients are often surprised to learn that lines and wrinkles are not the only signs of aging. As you age, the cheeks can lose volume and can sag. This is a result of age-related volume loss.3

JUVEDERM® XC is used to  correct moderate to severe lines and wrinkles on the lower face including those around the nose and mouth such as parentheses lines or 'smile lines.'4 To address age-related volume loss, I use JUVEDERM VOLUMA® XC.  It's the first and only FDA-approved hyaluronic acid filler specifically developed to add volume to the cheek area in adults over the age of 213and it can provide contour and a subtle lift to the midface.

2.   How long will the results last? 

JUVEDERM® XC lasts up to one year with optimal treatment,4 while JUVEDERM VOLUMA® XC is the only HA dermal filler that lasts up to two years with optimal treatment.3

3.   What will the results look like?

This is probably the question I get asked the most from patients. They don't want to walk out of my office looking drastically different or like they have had something done. After treatment with JUVEDERM® XC, patients will still look like themselves but their wrinkles and folds around their nose and mouth will be less noticeable.  For patients with age-related volume loss, JUVEDERM VOLUMA® XC instantly provides contour, a subtle lift to the cheeks and helps temporarily restore a more youthful-looking profile to the face.3

4.   What can I expect during the treatment?

These are non-surgical treatments that can be performed in the doctor's office in under an hour.  Both JUVEDERM® XC and JUVEDERM VOLUMA® XC contain a small amount of lidocaine which helps to numb the treatment area during the injection procedure and helps provide patient comfort.3,4

For JUVEDERM® XC, most side effects are mild or moderate in nature, and last 7 days or less. The most common side effects include temporary injection-site reactions such as: redness, pain/tenderness, firmness, swelling, lumps/bumps, bruising, itching, and discoloration. For JUVEDERM VOLUMA® XC, side effects are moderate (uncomfortable), and generally last 2 to 4 weeks. The most common side effects include temporary reactions at the treatment site such as tenderness, swelling, firmness, lumps/bumps, bruising, pain, redness, discoloration, and itching. As with all skin-injection procedures, there is a risk of infection.

It is important that fillers be administered by a licensed and trained healthcare professional who has experience with the product and knowledge of facial anatomy in order to achieve the best possible outcome.

5.    What's the difference between the currently available fillers?

Fillers can be made using different manufacturing techniques. JUVEDERM® XC is manufactured using Allergan's proprietary HYLACROSS™ technology, creating a smooth-consistency gel that flows easily and consistently. JUVEDERM VOLUMA® XC is formulated using Allergan's proprietary VYCROSS® technology, which contributes to lift capacity and duration and creates a smooth gel.3

Since its FDA approval in October 2013, JUVEDERM VOLUMA® XC has received the "Best Anti-Aging Treatment" award from NewBeauty Magazine5 and a "2014 Breakthrough Award" as part of Allure Magazine's annual Best of Beauty list.6

Consumers can visit www.Juvederm.com to learn more about both of these products in the JUVEDERM® Family of Fillers, the number one selling family of dermal filler products in the world.7  They can also search for a healthcare professional who will help determine if JUVEDERM®XC or JUVEDERM VOLUMA® XC is right for them.

JUVEDERM® XC AND JUVEDERM VOLUMA® XC IMPORTANT SAFETY INFORMATION

APPROVED USES
JUVEDERM® XC injectable gel is for injection into areas of facial tissue where moderate to severe facial wrinkles and folds occur to temporarily add volume to the skin, especially around the nose and mouth.

JUVEDERM VOLUMA® XC injectable gel is for deep injection in the cheek area to correct age-related volume loss in adults over the age of 21.

IMPORTANT SAFETY INFORMATION

Are there any reasons why I should not receive JUVEDERM® XC or JUVEDERM VOLUMA® XC?
Do not use these products if you have a history of multiple severe allergies or severe allergic reactions (anaphylaxis), or if you are allergic to the proteins (gram-positive bacterial proteins) used to make the hyaluronic acid (HA) in these products. Do not use JUVEDERM® XC or JUVEDERM VOLUMA® XC if you are allergic to lidocaine.

What precautions should my doctor advise me about?

  • The safety of JUVEDERM® XC and JUVEDERM VOLUMA® XC injectable gels for use during pregnancy or in women who are breastfeeding has not been studied
  • The safety of JUVEDERM® XC for use in patients under 18 years and JUVEDERM VOLUMA® XC for patients under 35 years or over 65 years has not been studied
  • The safety and effectiveness of JUVEDERM® XC for treatment of areas other than facial wrinkles and folds (such as lips) have not been established in clinical studies
  • The safety and effectiveness of JUVEDERM VOLUMA® XC for treatment in areas other than the cheek area have not been established in clinical studies
  • The safety of JUVEDERM® XC and JUVEDERM VOLUMA® XC in patients with a history of excessive scarring (eg, hypertrophic scarring and keloid formations) and pigmentation disorders has not been studied, and use may result in additional scars or changes in pigmentation
  • The safety of JUVEDERM VOLUMA® XC in patients with very thin skin in the cheek area and the safety of repeat treatments in patients has not been studied
  • There is a possible risk of inflammation at the treatment site if laser procedures and chemical peeling are performed after treatment
  • Patients who experience skin injury near the site of injection with these products may be at a higher risk for side effects
  • Tell your health care professional if you are on therapy used to decrease the body's immune response (immunosuppressive therapy). Use of these products may result in an increased risk of infection
  • Tell your health care professional if you are using medications that can prolong bleeding, such as aspirin, ibuprofen, or other blood thinners, as this may result in increased bruising or bleeding at the injection site
  • Minimize strenuous exercise and exposure to extensive sun or heat within the first 24 hours following treatment with JUVEDERM VOLUMA® XC

What are possible side effects?
For JUVEDERM® XC, most side effects are mild or moderate in nature, and last 7 days or less. The most common side effects include temporary injection-site reactions such as: redness, pain/tenderness, firmness, swelling, lumps/bumps, bruising, itching, and discoloration.

For JUVEDERM VOLUMA® XC, side effects are moderate (uncomfortable), and generally last 2 to 4 weeks. The most common side effects include temporary reactions at the treatment site such as tenderness, swelling, firmness, lumps/bumps, bruising, pain, redness, discoloration, and itching.

As with all skin-injection procedures, there is a risk of infection.

To report a side effect with JUVEDERM® XC or JUVEDERM VOLUMA® XC, please call Allergan Product Surveillance at 1-800-624-4261.

For more information, please see the Frequently Asked Questionspage at www.juvederm.com or call the Allergan Medical Information line at 1-800-433-8871.

JUVEDERM® XC and JUVEDERM VOLUMA® XC injectable gels are available by prescription only.

About Allergan

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential. Today, we have approximately 10,500 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to: www.allergan.com.

References
1 2014 Plastic Surgery Statistics Report. The American Society of Plastic Surgeons.
2 Allergan Data on File.
3 JUVEDERM VOLUMA® XC Patient Label 2013
4JUVEDERM VOLUMA® XC Patient Label 2013
5 NewBeauty  Magazine, Winter/Spring 2015
6 Allure Magazine, October, 2014
7 Data on File, Allergan, Inc., December 2013; Worldwide Dermal Facial Filler Market Overview

© 2015 Allergan, Inc. Irvine, CA 92612.
® marks owned by Allergan, Inc.

SOURCE Allergan

Related Links

http://www.juvederm.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.